Company’s 36-month beta value is 0.53.Analysts have differing opinions on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for PIRS is 91.57M, and currently, short sellers hold a 0.15% ratio of that floaft. The average trading volume of PIRS on April 19, 2024 was 601.97K shares.
PIRS) stock’s latest price update
Pieris Pharmaceuticals Inc (NASDAQ: PIRS)’s stock price has plunge by -1.18relation to previous closing price of 0.16. Nevertheless, the company has seen a -11.99% plunge in its stock price over the last five trading sessions. Zacks Investment Research reported 2023-09-25 that Pieris Pharmaceuticals (PIRS) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
PIRS’s Market Performance
PIRS’s stock has fallen by -11.99% in the past week, with a monthly drop of -27.96% and a quarterly drop of -6.76%. The volatility ratio for the week is 8.36% while the volatility levels for the last 30 days are 8.32% for Pieris Pharmaceuticals Inc The simple moving average for the past 20 days is -14.00% for PIRS’s stock, with a -29.78% simple moving average for the past 200 days.
Analysts’ Opinion of PIRS
Many brokerage firms have already submitted their reports for PIRS stocks, with Robert W. Baird repeating the rating for PIRS by listing it as a “Outperform.” The predicted price for PIRS in the upcoming period, according to Robert W. Baird is $5 based on the research report published on March 13, 2020 of the previous year 2020.
Robert W. Baird gave a rating of “Outperform” to PIRS, setting the target price at $5 in the report published on May 14th of the previous year.
PIRS Trading at -11.01% from the 50-Day Moving Average
After a stumble in the market that brought PIRS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.63% of loss for the given period.
Volatility was left at 8.32%, however, over the last 30 days, the volatility rate increased by 8.36%, as shares sank -26.05% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -10.59% lower at present.
During the last 5 trading sessions, PIRS fell by -11.96%, which changed the moving average for the period of 200-days by -8.86% in comparison to the 20-day moving average, which settled at $0.1778. In addition, Pieris Pharmaceuticals Inc saw -14.70% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PIRS starting from KIRITSY CHRISTOPHER P, who purchase 10,000 shares at the price of $0.85 back on May 25 ’23. After this action, KIRITSY CHRISTOPHER P now owns 20,000 shares of Pieris Pharmaceuticals Inc, valued at $8,500 using the latest closing price.
Stock Fundamentals for PIRS
Current profitability levels for the company are sitting at:
- -0.72 for the present operating margin
- 0.95 for the gross margin
The net margin for Pieris Pharmaceuticals Inc stands at -0.55. The total capital return value is set at -1.15. Equity return is now at value -89.76, with -36.58 for asset returns.
Currently, EBITDA for the company is -14.06 million with net debt to EBITDA at -4.49. When we switch over and look at the enterprise to sales, we see a ratio of -0.05. The receivables turnover for the company is 7.09for trailing twelve months and the total asset turnover is 1.11. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.24.
Conclusion
In a nutshell, Pieris Pharmaceuticals Inc (PIRS) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
